Last reviewed · How we verify
Adalimumab Every Week
Adalimumab is a TNF-alpha inhibitor monoclonal antibody that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity.
Adalimumab is a TNF-alpha inhibitor monoclonal antibody that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity. Used for Rheumatoid arthritis, Psoriasis, Crohn's disease.
At a glance
| Generic name | Adalimumab Every Week |
|---|---|
| Also known as | HUMIRA |
| Sponsor | Innovaderm Research Inc. |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Adalimumab binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking TNF-alpha signaling, it suppresses the inflammatory cascade and reduces disease progression. The weekly dosing regimen represents a modified administration schedule of the established adalimumab molecule.
Approved indications
- Rheumatoid arthritis
- Psoriasis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Opportunistic infections
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (PHASE3)
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) (PHASE2)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |